John Forbes

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Aron Goldhirsch, Eric P. Winer, Alan S. Coates et al. · Annals of Oncology · 2013 · 3.7K citations · Full text

Medicine, Oncology, Breast Oncology +10

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

Anthony Howell, Jack Cuzick, M Baum et al. · The Lancet · 2005 · 2.3K citations

Medicine, Oncology, Breast Oncology +6

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text

Medicine, Endocrinology, Oncology +14

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

Alan S. Coates, Eric P. Winer, Aron Goldhirsch et al. · Annals of Oncology · 2015 · 1.8K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Jack Cuzick, Ivana Šestak, Michael Baum et al. · The Lancet Oncology · 2010 · 1.7K citations

Medicine, Oncology, Pharmacology +15